GlassScriptPhysician profile
Bibinaz Eghtedari
NPI 1619506763
$4,055.89
in general payments reported to CMS, 2019-2025
25 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2023: $969 · 2024: $1,219 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,595 · Education: $238 · Gift: $86.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,595.17 |
| Education | $237.70 |
| Gift | $86.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $839.36 | 2025 | Rapiblyk |
| Boston Scientific Corporation | $421.47 | 2021-2025 | Ekosonic, Resonate El Icd Vr, Rotapro |
| Shockwave Medical, INC | $314.71 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $279.29 | 2024-2025 | |
| Abiomed | $269.55 | 2024-2025 | Impella |
| Amgen INC. | $267.24 | 2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $244.78 | 2023-2024 | Camzyos |
| Abbott Laboratories | $237.70 | 2023 | Ensite |
| Regeneron Healthcare Solutions, INC. | $213.94 | 2024-2025 | Evkeeza |
| Heartflow, INC. | $175.82 | 2025 | |
| Pfizer INC. | $158.12 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $111.54 | 2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $86.95 | 2023-2024 | Inpefa |
| Terumo Medical Corporation | $57.13 | 2023 | Tr Band |
| Kiniksa Pharmaceuticals International, Plc | $52.67 | 2024 | Arcalyst |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $48.13 | 2025 | |
| Lantheus Medical Imaging, INC. | $47.81 | 2023-2024 | Definity |
| Edwards Lifesciences Corporation | $37.11 | 2025 | Sapien 3 Ultra Resilia |
| United Therapeutics Corporation | $31.60 | 2025 | Tyvaso |
| Invivyd INC | $31.36 | 2025 | Pemgarda |
| Csl Behring | $30.48 | 2025 | Kcentra |
| Merck Sharp & Dohme LLC | $27.49 | 2025 | Winrevair |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.70 | 2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.00 | 2023 | Jardiance |
| Bridgebio Pharma, INC. | $18.94 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bibinaz Eghtedari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.